SEC Form 4 · accession 0000899243-18-030040
Unity Biotechnology, Inc. · UBX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Margo R Roberts
Director
Period of report
Dec 3, 2018
Accepted (ET)
Dec 4, 2018 · 4:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001463361
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $13.67 | Dec 3, 2018 | A | 50,661 | A | — | Dec 2, 2028 | Common Stock | 50,661 | 50,661 | D |
Explanation of responses
- F1The number of shares underlying the option grant is based on a grant date value of $450,000, which is calculated using the Black-Scholes pricing model with the volume weighted average trading price of a share of Common Stock on the stock exchange on which the Common Stock is then listed or traded for the thirty (30) consecutive trading days ending on the trading day prior to the date of grant and the volatility, risk-free rate and life expectancy assumptions in the Company's most recent public filings disclosing those assumptions.
- F2The shares subject to the option will vest and become exercisable with respect to 1/36th of the total number of shares subject to the option in successive, equal monthly installments measured from December 3, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.